Flexible Solutions International (NYSE:FSI) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded Flexible Solutions International (NYSE:FSI) from a “strong sell” to a “hold” rating in a Monday report. FSI opened at $6.45; it has a $82.15M market cap and trades near $6.34 (50-day) and $6.11 (200-day). The company reported $0.06 EPS for the April 15 quarter, down from $0.24 a year earlier.

Original reporting
Published Jun 24, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Flexible Solutions International (NYSE:FSI) Upgraded by Zacks Research to “Hold” Rating — source image
Decision brief

The 30-second read

$FSINeutralLow
01

Why it matters

The only new decision-relevant item is Zacks’ rating upgrade from “strong sell” to “hold,” which can influence sentiment but does not introduce new financial guidance or operational developments.

02

Market read

Traders may adjust short-term sentiment around FSI on the upgrade, but the lack of new fundamentals suggests limited follow-through risk/reward.

03

What to watch

The article includes prior-quarter EPS and institutional buying, but it does not connect those to the upgrade thesis or provide new forward estimates/targets.

Relevance 4/10Novelty 5/10Timing: after-hours/next-session positioning following Monday’s Zacks rating change

Background

FSI is a specialty chemical company focused on polymer-based and bio-based additives; it last reported quarterly EPS on April 15.

Company-level read

Ticker impact

$FSINeutralMedium confidence
Context

Zacks upgraded Flexible Solutions International from a “strong sell” to a “hold,” a fresh sell-side rating change for FSI.

Expected impact

Near-term reaction likely muted; any move should fade unless accompanied by new fundamentals beyond the rating change.

Evidence & confidence

The article provides only the rating change (no new earnings/guidance, targets, or fundamental datapoint) and frames it as a downgrade-to-hold rather than a bullish re-rating.

Market effects

Limited read-across to specialty chemicals; this is a single-name analyst action without sector-wide catalyst.

No specific regional linkage beyond the company’s Ohio base.

No global macro or cross-border transaction details.

Counterpoint

Because the rating only moves to “hold,” the market may treat it as incremental noise versus catalysts like guidance, contracts, or margin changes.

Key entities

  • Flexible Solutions International

    Specialty chemical producer of polymer modifiers, specialty resins, and performance additives; subject of the Zacks rating upgrade.

  • Zacks Research

    Equities research provider that upgraded FSI’s rating to “hold” from “strong sell” in a Monday report.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$SHAZMed

What SharonAI (SHAZ) Said on Its Q3 Earnings Call

SharonAI (SHAZ) reported Q3 earnings, highlighting a $1.32B agreement and new contracts totaling $1.17B. The company terminated a $373M contract due to credit risk. CFO Anuj Goel noted $2.6B in capital secured since December 2025, with $1.3B in cash as of Sept. 30. The NVIDIA AICP program covers 72MW and 40,000 GPUs, with billing expected from Q3 2027. SharonAI plans to fund build-out with secured debt and expects $800M in customer deposits.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$UALMed

United Airlines system outage disrupts departures, 418 flights delayed

United Airlines experienced a system outage causing 418 flight delays. The issue affected departing flights and pilot applications, but not in-air flights or United Express services. The airline resolved the outage, attributing it to a technology issue, not cybersecurity. Recent U.S. tech disruptions include JPMorgan Chase's banking service delays and an FAA air traffic control system malfunction.

$BAMed

First permanently assigned F-15EXs touch down at Kadena Air Base

Kadena Air Base in Japan received two permanently assigned F-15EX Eagle II fighter jets, marking the first overseas U.S. base to do so. The Air Force aims to boost airpower in the Pacific, replacing older F-15C/D models. The jets, with advanced avionics and weapons capacity, will support operations with Japan and regional partners. Boeing received a $2.38 billion contract for 22 more F-15EXs, increasing the total to 120.